NeuroSigma, Inc., a bioelectronics company based in Los Angeles, has completed an investment of approximately $1 million aimed at scaling manufacturing for its innovative ADHD treatment device, the Monarch external Trigeminal Nerve Stimulation (eTNS). This strategic move, made in collaboration with Singapore-based Armstrong Asia, is designed to support the anticipated launch of the second-generation Monarch device in the first quarter of 2026.
The funding, led by Pasadena’s Checkmate Capital, will facilitate the establishment of a high-volume manufacturing line. This line will focus on producing the second-generation Monarch eTNS device, which is designed to treat pediatric attention-deficit/hyperactivity disorder. In November 2025, NeuroSigma announced the successful completion of its pilot commercialization program for the first-generation device, indicating strong market interest.
Dr. Colin Kealey, President and Chief Executive Officer of NeuroSigma, expressed enthusiasm for the investment. He stated, “This investment enables cost-efficient and scalable manufacturing of the second-generation Monarch eTNS device. As we move into 2026, we look forward to working with Armstrong Asia to deliver this innovative product to patients and families throughout the world.”
The Monarch eTNS device is notable for being the first wearable medical device to gain clearance from the U.S. Food and Drug Administration (FDA) as a drug-free treatment for ADHD. The upcoming second-generation version will maintain the same therapeutic mechanism—trigeminal nerve stimulation—while incorporating a simplified user interface for ease of use.
Strategic Collaboration and Market Outlook
The partnership between NeuroSigma, Armstrong Asia, and Checkmate Capital extends beyond manufacturing. It is part of a broader collaboration that focuses on cross-border transactions in the life sciences and medical technology sectors. Tom Paschall, Chief Executive of Checkmate Capital and a director at NeuroSigma, highlighted the favorable conditions within the medical device industry. He remarked, “The Monarch eTNS device is a groundbreaking neuro-electronic product that provides patients, families, and physicians with an alternative to stimulant medications and the negative side effects associated with them.”
NeuroSigma’s commitment to innovation and patient care is evident in its strategic decisions. The company aims to address the growing demand for effective ADHD treatments that do not rely on traditional stimulant medications. As the launch date approaches, stakeholders are keenly observing how the second-generation Monarch eTNS device will be received in the market.
The investment in manufacturing is not just a financial commitment; it represents NeuroSigma’s confidence in the potential impact of its device on the lives of children with ADHD. With the backing of experienced partners and a clear vision for the future, NeuroSigma is poised to make significant strides in the field of neurostimulation therapy.
This investment marks a pivotal moment for NeuroSigma as it prepares to scale operations and enhance accessibility to its innovative ADHD treatment solutions.
